We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparison of Three Different Formulations of Prednisolone Acetate 1%

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00345046
Recruitment Status : Completed
First Posted : June 27, 2006
Results First Posted : April 21, 2014
Last Update Posted : June 3, 2015
Sponsor:
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Conditions: Glaucoma
Cataract
Interventions: Drug: Pred Forte
Drug: EconoPred Plus
Drug: Prednisolone Acetate

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Recruitment period Feb 2005 - Jun 2008 Subjects were recruited from surgical schedule.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
One subject was disqualified due to previous laser treatment. One subject did not receive study medication therefore was discontinued from study participation.

Reporting Groups
  Description
Pred Forte 1% Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.
EconPred Plus 1% EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.
Prednisolone Acetate 1% Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.

Participant Flow:   Overall Study
    Pred Forte 1%   EconPred Plus 1%   Prednisolone Acetate 1%
STARTED   18   22   16 
COMPLETED   17   21   14 
NOT COMPLETED   1   1   2 
Protocol Violation                1                1                2 



  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Pred Forte

Pred Forte 1% dosed four times daily decreasing to once daily over four weeks.

Pred Forte: Four drops daily decreasing to once daily over four weeks.

EconoPred Plus

EconoPred Plus 1% dosed four times daily decreasing to once daily over four weeks.

EconoPred Plus: Prednisolone Acetate four times daily decreasing to once daily over four weeks.

Prednisolone Acetate

Prednisolone Acetate 1% dosed four times daily decreasing to once daily over four weeks.

Prednisolone Acetate: Dosed four times daily decreasing to once daily over four weeks.

Total Total of all reporting groups

Baseline Measures
   Pred Forte   EconoPred Plus   Prednisolone Acetate   Total 
Overall Participants Analyzed 
[Units: Participants]
 18   21   12   51 
Age 
[Units: Years]
Mean (Standard Deviation)
 64.8  (15.2)   68.3  (13.0)   65.7  (16.6)   66.5  (14.5) 
Gender 
[Units: Participants]
       
Female   10   8   7   25 
Male   8   13   5   26 


  Outcome Measures

1.  Primary:   Percent Change in Flare at Resolution   [ Time Frame: 2 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Louis B. Cantor
Organization: Indiana University
phone: 317-278-2651
e-mail: lcantor@iupui.edu


Publications:
Fiscella RG, Gutta R, Goldstein DB, Viana MAG. Comparison of PredForte Brand to generic Prednisolone acette and loteprednol etabonate (lotemax) in a Rabbit Model of Inflammation. American Academy of Ophthalmology 2001 Annual Meeting, Poster 73 Session 2001.


Responsible Party: Indiana University ( Indiana University School of Medicine )
ClinicalTrials.gov Identifier: NCT00345046     History of Changes
Other Study ID Numbers: 0201-28
First Submitted: June 26, 2006
First Posted: June 27, 2006
Results First Submitted: December 24, 2013
Results First Posted: April 21, 2014
Last Update Posted: June 3, 2015